All In Biotech

NDA 215383 · Merck Sharp Dohme

Welireg

Belzutifan · Oral · Hypoxia-inducible Factor Inhibitor

NovelPriority reviewOrphan

CDER novel approval, Aug 13, 2021: To treat von Hippel-Lindau disease under certain conditions

Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Aug 13, 2021

Approved uses

7

Original approval plus efficacy supplements

Registered trials

45

8 Phase 3, 14 recruiting

FAERS reports

1,777

1,224 serious, 167 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. FDA's summary: To treat von Hippel-Lindau disease under certain conditions

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • WELIREG · BELZUTIFAN 40MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Belzutifan" as an intervention, any sponsor and status, largest first.

All 45 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • anaemia329
  • malignant neoplasm progression262
  • hypoxia174
  • fatigue129
  • death80
  • dyspnoea70
  • diarrhoea66
  • haemoglobin decreased65
  • off label use65
  • oxygen saturation decreased61
  • nausea59
  • therapy interrupted57

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
202139
2022315
2023388
2024179
2025234
2026622

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Welireg (Belzutifan)

2024 spending

$205M

Beneficiaries

1,896

7,964 claims

Per beneficiary

$108,365

$323.85 per unit

View as table
YearSpending
2020$0
2021$3,981,413
2022$29,705,807
2023$59,823,810
2024$205,460,496

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 23 on PubMed
PubMed could not be reached. The numbers below may be missing or incomplete.

No PubMed clinical studies matched.

Sponsor: Merck & Co.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.